BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Zydus and Lupin sign licensing agreement for co-marketing Semaglutide injection in India

17 March 2026 | News

Zydus will market the product under the brand names â?? SEMAGLYN, MASHEMA and ALTERME



Zydus Lifesciences has entered into a Licensing and Supply Agreement with global pharma major, Lupin to expand access to innovative Semaglutide Injection (15 mg/3 ml) with patient-friendly reusable pen device in India.

This partnership brings together Zydus' strong product development capabilities and Lupin's extensive reach in the Indian market, with the shared objective of bringing advanced therapies for metabolic disorders.

Under this agreement, Lupin will have semi-exclusive rights to co-market Zydus' innovative Semaglutide Injection in the Indian market under the brand names Semanext® and Lupin's Livarise®. Zydus will market the product under the brand names SEMAGLYN™, MASHEMA™ and ALTERME™. Lupin will pay Zydus upfront licensing fees and milestone payments on achieving pre-defined milestones.

Speaking on the development, Dr Sharvil Patel, Managing Director, Zydus Lifesciences Ltd., said, "Our life-changing discoveries are empowering patients to live healthier, more fulfilling lives. Keeping patients' needs and convenience at the very core, the innovative pen device we are offering is designed to make therapy simpler and improve quality of life. We are pleased to join hands with Lupin to broaden access to this medicine and the novel patient-friendly delivery device, thereby expand its reach across India."

Nilesh Gupta, Managing Director, Lupin, said, " Our partnership with Zydus to market Semaglutide injection in India is a significant step in strengthening our commitment to providing advanced treatment options for cardio-metabolic diseases. As GLP 1 therapies continue to redefine treatment standards globally, this collaboration enhances our diabetes portfolio and reinforces our focus on addressing unmet patient needs. Together, we aim to expand access to innovative, high-quality treatment options for patients and support healthcare professionals across India."